Terence Friedlander, MD, University of California, San Francisco, CA, discusses updated results from Cohort K of the Phase Ib/II EV-103...

Antonio Llombart Cussac, MD, PhD, Arnau de Vilanova Hospital of Valencia, Valencia, Spain, discusses results from the Phase II EMPRESS...

Janice Wing-Hang Tsang, MBBS, MRCP, FRCP, University of Hong Kong, Hong Kong, China, provides an overview of the metastatic breast...

Emmanuel Seront, MD, PhD, Cliniques Universitaires Saint Luc, Brussels, Belgium, discusses the Phase II RENALUT (NCT06783348) of 177Lu-PSMA-617 in patients...

Charles Geyer, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, discusses results from the Phase III DESTINY-Breast05 trial (NCT04622319), comparing...

Nima Nabavizadeh, MD, Oregon Health & Science University, Portland, OR, discusses the PATHFINDER II study (NCT05155605), evaluating a multi-cancer early...

Neal Shore, MD, FACS, Carolina Urologic Research Center, Myrtle Beach, SC, discusses final overall survival results from the Phase III...

Alexandra Drakaki, MD, PhD, University of California, Los Angeles, CA, discusses the Phase I FORAGER-1 study (NCT05614739) of LY3866288, a...

Shigehira Saji, MD, PhD, Fukushima Medical University, Fukushima, Japan, comments on discusses final survival results from the EMERALD study (NCT03264547)...

Andreas Dietz, MD, PhD, University Hospital of Leipzig, Leipzig, Germany, discusses the Phase IIb ADRISK trial (NCT03480672), which evaluated pembrolizumab...

Enrique Grande, MD, MD Anderson Cancer Center Madrid, Madrid, Spain, discusses the Phase II DISCUS trial (NCT06892860), which evaluated whether...

Clara Steiner, MD, Dana-Farber Cancer Institute, Boston, MA & University Hospital Leipzig, Leipzig, Germany, discusses a post-hoc transcriptomic analysis from...

Alexander Wyatt, DPhil, University of British Columbia, Vancouver, Canada, discusses the Phase III IMvigor011 trial (NCT04660344) of circulating tumor (ctDNA)-guided...

Shigehira Saji, MD, PhD, Fukushima Medical University, Fukushima, Japan, discusses the MonarchE trial (NCT03155997) evaluating the prognostic and predictive value...

Scott Tagawa, MD, MS, FACP, Weill Cornell Medical Center, New York, NY, discusses the Phase III PSMAddition trial (NCT04720157), which...

Clara Steiner, MD, Dana-Farber Cancer Institute, Boston, MA & University Hospital Leipzig, Leipzig, Germany, gives an overview of updated 5-year...

Stephanie Graff, MD, Brown University Health Cancer Institute, Providence, RI, joins us for an “Ask the Expert” session at ESMO...

Emmanuel Seront, MD, PhD, Cliniques Universitaires Saint Luc, Brussels, Belgium, discusses the Phase II RENALUT (NCT06783348) of 177Lu-PSMA-617 in patients...

Jun Ma, MD, Sun Yat-sen University Cancer Center, Guangzhou, China, comments on the potential benefits of integrating PD-1 immunotherapy (IO)...

Cecile Riviere-Cazaux, PhD, Mayo Clinic, Rochester, MN, highlights the emerging role cell-free DNA (cfDNA) as novel biomarkers in neuro-oncology, highlighting...

Jun Ma, MD, Sun Yat-sen University Cancer Center, Guangzhou, China, discusses current immunotherapy approaches in nasopharyngeal carcinoma. There is a...

Christina Fotopoulou, MD, PhD, Imperial College London, London, UK, emphasizes the importance of accessibility as a major barrier in providing...

Aslı Doğa Munzur, BSc, Vancouver Prostate Centre, Vancouver, Canada, speaks on the potential of clonal hematopoiesis (CH) as a biomarker...

Fabrice André, MD, PhD, Gustave Roussy, Villejuif, France, shares his rationale against the continuation of CDK4/6 inhibitors following disease progression...

Christina Fotopoulou, MD, PhD, Imperial College London, London, UK, discusses the TRUST study (NCT02828618), a prospective randomized trial on the...

Jason Mouabbi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of key studies in...

Swati Kulkarni, MD, Northwestern University Feinberg School of Medicine, Chicago, IL, discusses the Phase II PROMISE study (NCT02694809), which assesses...

Fabrice André, MD, PhD, Gustave Roussy, Villejuif, France, discusses the Phase III KEYNOTE-756 study (NCT03725059) of pembrolizumab with neoadjuvant chemotherapy...

Felix Hilpert, MD, Krankenhaus Jerusalem, Hamburg, Germany, gives an overview of treatment gaps in elderly and frail patients with ovarian...

Yue Che, MD, University Hospital of Duesseldorf, Düsseldorf, Germany, discusses the evolving role of retroperitoneal lymph node dissection and therapy...

Michael Gnant, MD, FACS, Medical University of Vienna, reviews four key studies on long-term endocrine therapy in premenopausal HR+ breast...

Domenica Lorusso, MD, PhD, Fondazione IRCCS National Cancer Institute of Milan, Milan, Italy, discusses secondary endpoint findings from the Phase...

Peter Albers, German Cancer Research Center (DKFZ), Heidelberg & Heinrich-Heine-University, Düsseldorf, Germany, comments on the PROBASE trial of risk adapted...

Alberto Farolfi, MD, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST), Dino Amadori, Meldola, Italy, describes the limitations of...

Stephen Bagley, MD, MSCE, University of Pennsylvania, Philadelphia, PA, suggests that integrating cerebrospinal fluid (CSF) collection into therapeutic clinical trials...

Samer Srour, MB ChB, MS, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on an ongoing Phase...

Nadia Hindi, MD, Fundación Jimenez Diaz University Hospital, Madrid, Spain, comments on the limitations of comparing immune checkpoint inhibitors in...

Cecile Riviere-Cazaux, PhD, Mayo Clinic, Rochester, MN, comments on the potential of cerebrospinal fluid (CSF)-based biomarkers in clinical trials for...

Paolo Tarantino, MD, Dana-Farber Cancer Institute, Boston, MA, comments on a quantitative pre-treatment evaluation of HER2 and topoisomerase 1 (Topo1)...

Suneel Kamath, MD, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, shares his insights on the current funding disparities and the...

Inimfon Jackson, MD, PhD, MPH, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses disparities in chemotherapy acceptance...

Chinmay Jani, MBBS, Sylvester Comprehensive Cancer Center, Doral, FL, comments on the potential relationship between alcohol consumption and cancer mortality,...

Xiaoqian Nie, PhD, Westlake University, Hangzhou, China, shares results of a Phase I trial (NCT06026605) investigating erythrocyte-antibody conjugates in cancers...

John Paul Shen, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, compares recent methylation-based tissue free testing...

Francois Doz, MD, Institut Curie, Paris, France, emphasizes the potential of precision medicine in pediatric cancers, particularly in cases like...

Manmeet Ahluwalia, MD, MBA, FASCO, Baptist Health South Florida, Miami, FL, provides an overview of the evolving treatment landscape for...

Mario Perro, PhD, Ichnos Glenmark Innovation, New York, NY, discusses the preclinical profile of GRC 65327, a highly selective and...

Manas Pustake, MD, Texas Tech University Health Science Center, El Paso, TX, comments on the significant disparities in cancer screening...

Valentina Marulanda Corzo, MD, Weill Cornell Medicine, New York, NY, discusses findings from early-phase trials (NCT03276572, NCT04506567, NCT04886986, NCT04946370) assessing...

Michael Ong, MD, BSc, FRCPC, The Ottawa Hospital Cancer Centre, Ottawa, Canada, comments on a real-world analysis from the IRONMAN...